The growth of knowledge about the molecular mechanisms underlying Alzheimer's disease
(AD) has highlighted the role of neuroinflammation in the pathophysiology of this disorder …

Given the complex heterogeneity of pathological changes occurring in Alzheimer's disease
(AD), any therapeutic effort absolutely requires a multi-targeted approach, because attempts …

Background In addition to cytotoxic mechanisms directly impacting neurons, β-amyloid (Aβ)-
induced glial activation also promotes release of proinflammatory molecules that may self …

Alzheimer's disease (AD) is a neurodegenerative disorder responsible for the majority of
dementia cases in elderly people. It is widely accepted that the main hallmarks of AD are not …

N-palmitoylethanolamide (PEA) is a lipid mediator belonging to the class of the N-
acylethanolamine. Products containing PEA, also in ultramicronized formulation (um-PEA) …

Background: Based on the pivotal role of astrocytes in brain homeostasis and the strong
metabolic cooperation existing between neurons and astrocytes, it has been suggested that …

The available treatments for patients affected by Alzheimer's disease (AD) are not curative.
Numerous clinical trials have failed during the past decades. Therefore, scientists need to …

N-Palmitoylethanolamide (PEA) is a non-endocannabinoid lipid mediator belonging to the
class of the N-acylethanolamine phospolipids and was firstly isolated from soy lecithin, egg …

Aβ-induced astrogliosis can worsen the eziopathogenesis of Alzheimer disease (AD) by the
release of proinflammatory and pro-oxidant mediators. Activated glial cells may release also …

Palmitoylethanolamide (PEA), the naturally occurring amide of ethanolamine and palmitic
acid, is an endogenous lipid compound endowed with a plethora of pharmacological …